MaxCyte^® Enables Rapid, High-Yielding, Stable Cell Line Development

This study explores the use of MaxCyte's Flow Electroporation^® in developing stable monoclonal CHO cell lines for biotherapeutic production. The traditional process of creating these cell lines is time-consuming, costly, and requires specialized equipment. The study introduces a method that enables the creation of high-yielding stable CHO clones within six weeks of transfection. This method involves electroporation, culture, selection, and limiting dilution and screening. The top-performing clone was identified within this timeframe, demonstrating high productivity and yield. The study concludes that MaxCyte's technology simplifies and accelerates CHO-S stable cell line development, eliminating the need for extensive screening of candidate clones and specialized equipment.